Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure-Reference-Cited by-同舟云学术

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

Published:2013-09-18 Issue:11 Volume:139 Page:1937-1946
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Pönisch Wolfram,Moll Barbara,Bourgeois Malvina,Andrea Marc,Schliwa Thomas,Heyn Simone,Schmalfeld Marion,Edelmann Thomas,Becker Cornelia,Hoffmann Franz Albert,Schwarzer Andreas,Kreibich Ute,Egert Matthias,Stiegler Runa,Krahl Rainer,Remane Yvonne,Bachmann Anette,Lindner Tom,Weidhase Lorenz,Petros Sirak,Fricke Stefan,Vucinic Vladan,Al Ali Haifa,Niederwieser Dietger

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-013-1513-2.pdf

Reference36 articles.

1. Alexanian R, Barlogie B, Dixon D (1990) Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150:1693–1695

2. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Nassir Y, Swift RA, Mayo D (2013) Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 160:321–330

3. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ (2008) Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 6:352–355

4. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S (2007) Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109:2604–2606

5. Clark AD, Shetty A, Soutar R (1999) Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 13(2):79–90

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational study;Medicine;2024-06-28

2. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group;The Lancet Oncology;2023-07

3. Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis;Journal of Oncology Pharmacy Practice;2022-05-18

4. An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment;Therapeutic Advances in Hematology;2022-01

5. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma;Cancers;2021-10-04